Literature DB >> 28531884

Pre-Interventional Kynurenine Predicts Medium-Term Outcome after Contrast Media Exposure Due to Coronary Angiography.

Christoph Reichetzeder1,2, Fabian Heunisch1,2,3, Gina von Einem1,3, Oleg Tsuprykov1,2,4, Karl-Heinz Kellner5, Thomas Dschietzig6,7, Axel Kretschmer8, Berthold Hocher1,4,9.   

Abstract

BACKGROUND/AIMS: Contrast induced acute kidney injury (CI-AKI) remains a serious complication of contrast media enhanced procedures like coronary angiography. There is still a lack of established biomarkers that help to identify patients at high risk for short and long-term complications. The aim of the current study was to evaluate plasma kynurenine as a predictive biomarker for CI-AKI and long-term complications, measured by the combined endpoint "major adverse kidney events" (MAKE) up to 120 days after CM application.
METHODS: In this prospective cohort study 245 patients undergoing coronary angiography were analyzed. Blood samples were obtained at baseline, 24h and 48h after contrast media (CM) application to diagnose CI-AKI. Patients were followed for 120 days for adverse clinical events including death, the need for dialysis, and a doubling of plasma creatinine. Occurrence of any of these events was summarized in the combined endpoint MAKE.
RESULTS: Preinterventional plasma kynurenine was not associated with CI-AKI. Patients who later developed MAKE displayed significantly increased preinterventional plasma kynurenine levels (p<0.0001). ROC analysis revealed that preinterventional kynurenine is highly predictive for MAKE (AUC=0.838; p<0.0001). The optimal cutoff was found at ≥3.5 µmol/L Using this cutoff, the Kaplan-Meier estimator demonstrated that concentrations of plasma kynurenine ≥3.5 µmol/L were significantly associated with a higher prevalence of MAKE until follow up (p<0.0001). This association remained significant in multivariate Cox regression models adjusted for relevant factors of long-term renal outcome.
CONCLUSION: Preinterventional plasma kynurenine might serve as a highly predictive biomarker for MAKE up to 120 days after coronary angiography.
© 2017 The Author(s). Published by S. Karger AG, Basel.

Entities:  

Keywords:  Contrast induced acute kidney injury; Coronary angiography; Kynurenine; Major adverse kidney event; Preinterventional biomarker

Mesh:

Substances:

Year:  2017        PMID: 28531884     DOI: 10.1159/000477222

Source DB:  PubMed          Journal:  Kidney Blood Press Res        ISSN: 1420-4096            Impact factor:   2.687


  3 in total

Review 1.  The therapeutic potential of targeting tryptophan catabolism in cancer.

Authors:  Luis F Somarribas Patterson; Soumya R Mohapatra; Dyah L Dewi; Christiane A Opitz; Ahmed Sadik; Michael Platten; Saskia Trump
Journal:  Br J Cancer       Date:  2019-12-10       Impact factor: 7.640

Review 2.  Kynurenine pathway in kidney diseases.

Authors:  Izabela Zakrocka; Wojciech Załuska
Journal:  Pharmacol Rep       Date:  2021-10-06       Impact factor: 3.919

3.  DPP4 inhibition prevents AKI.

Authors:  Christoph Reichetzeder; Berthold Hocher
Journal:  Oncotarget       Date:  2017-08-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.